-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, V5gET5bAYQyOqTTCfXPA3Mg91w/Luxo7+Ny5/tEr5//GJa5TYaFvNCDF4WzI8YKu WAGBSYRYA69zmPETdSwuuQ== 0000893220-08-001904.txt : 20080624 0000893220-08-001904.hdr.sgml : 20080624 20080624095227 ACCESSION NUMBER: 0000893220-08-001904 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080618 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events FILED AS OF DATE: 20080624 DATE AS OF CHANGE: 20080624 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENELINK INC CENTRAL INDEX KEY: 0000941020 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 232795613 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30518 FILM NUMBER: 08913477 BUSINESS ADDRESS: STREET 1: PO BOX 3212 CITY: MARGATE STATE: NJ ZIP: 08402 BUSINESS PHONE: 6098236991 MAIL ADDRESS: STREET 1: PO BOX 3212 CITY: MARGATE STATE: NJ ZIP: 08402 8-K 1 w61589e8vk.htm FORM 8-K e8vk
 
 
United States
Securities and Exchange Commission
Washington, DC 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: June 18, 2008
GeneLink, Inc.
(Exact Name of Registrant as Specified in its Charter)
         
PA   00-30518   23-2795613
         
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
317 Wekiva Spring Road, #200, Longwood, FL 32779
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (800) 558-4363
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

ITEM 3.02   Unregistered Sales of Equity Securities
     On June 24, 2008, all remaining holders of the Company’s outstanding convertible secured promissory notes converted such notes into shares of the Company’s common stock at a conversion price of $0.05 per share. $882,041 of convertible secured promissory notes converted into an aggregate of 17,640,813 shares of Common Stock of the Company.
ITEM 8.01   OTHER EVENTS
     On or about June 18, 2008, in connection with the terms of the Order of Settlement dated May 13, 2008 (the “Settlement”) relating to the Action entitled, John R. DePhillipo v. GeneLink, Inc. (Superior Court of New Jersey Law Division: Atlantic County, Docket No. ATL-L-7479-05) the Company paid John DePhillipo $220,000, and the Company and Mr. DePhillipo exchanged mutual releases. As a result of such payment and the exchange of the mutual releases, all terms of the Settlement have been completed.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  GeneLink, Inc.
(Registrant)
 		  
  By:   /s/ Monte E. Taylor, Jr.    
    Monte E. Taylor, Jr.   
    Chief Executive Officer   
 
Dated: June 24, 2008

 

-----END PRIVACY-ENHANCED MESSAGE-----